Drug Trial Radar · NCT01323374
Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Jan 2009
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Chelsea TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A correlation between increased norepinephrine concentration in the central nervous system (CNS) and a decrease in fibromyalgia pain has been suggested in clinical studies. Therefore, as a pro-drug of norepinephrine, droxidopa could potentially benefit fibromyalgia patients by reducing pain as a result of increasing CNS levels of norepinephrine. As this benefit is presumed to be a central effect, the addition of carbidopa, a peripheral DOPA decarboxylase (DDC) inhibitor, may favorably impact the drug's treatment profile. Carbidopa is utilized as a blocker of peripheral DDC, an enzyme required for the conversion of droxidopa into norepinephrine. Therefore, inhibition of peripheral DDC should result in a reduction of any side effects resulting from the peripheral production of norepinephrine, whilst allowing for increased central levels, and hence, increased centrally mediated benefits. The purpose of the study is the obtain information regarding the proper dosing, effectiveness and safety of droxidopa and combination droxidopa/carbidopa treatments in patients with fibromyalgia.
Conditions
- Fibromyalgia
Interventions
DroxidopaDrug
Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
CarbidopaDrug
Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Droxidopa/carbidopaDrug
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
PlaceboDrug
Oral, placebo TID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the efficacy of droxidopa and droxidopa/carbidopa in the treatment of pain associated with fibromyalgiaTime frame: Baseline to end of 8 week treatment period
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Rheumatology Department; Barnsley Hospital NHS Foundation Trust
Barnsley, United Kingdom
MAC UK Neuroscience
Liverpool, United Kingdom
Academic Dept of Rheumatology, Kings College London
London, United Kingdom
MAC UK Neuroscience
Manchester, United Kingdom
Musculoskeletal Department; Freeman Hospital
Newcastle upon Tyne, United Kingdom
Rheumatology Department, Poole Hospital NHS Trust
Poole, United Kingdom
Clinical Trials Unit; Main Hospital; Salford Rooyal NHS Foundation Trust
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.